Telitacicept in the Treatment of Pediatric IgA Vasculitis-Associated Nephritis

To further evaluate the efficacy and safety of Telitacicept in the treatment of pediatric IgA vasculitis nephritis (IgAVN) within real-world settings, this study employs a multicenter, retrospective and prospective observational research design. It aims to compare the efficacy of Telitacicept with that of glucocorticoids, thereby providing clinicians with a reference for the rational and standardized application of Telitacicept.

NCT Number	NCT07354503
Lead Sponsor	The Children's Hospital of Zhejiang University School of Medicine
Conditions	IgAVN, IgA Vasculitis
Enrollment	300 participants
Start Date	2026-01-01
Primary Completion	2027-06-30 (estimated)
Study Completion	2028-06-30 (estimated)
Updated on ClinicalTrials.gov	2026-01-21